New York State Common Retirement Fund Purchases 103,931 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

New York State Common Retirement Fund boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 111.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 197,132 shares of the medical equipment provider’s stock after acquiring an additional 103,931 shares during the period. New York State Common Retirement Fund’s holdings in Lantheus were worth $17,635,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the third quarter valued at about $25,000. Kestra Investment Management LLC bought a new position in Lantheus during the fourth quarter worth about $27,000. Signaturefd LLC boosted its holdings in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares during the last quarter. UMB Bank n.a. boosted its holdings in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC bought a new position in Lantheus during the third quarter worth about $60,000. Institutional investors own 99.06% of the company’s stock.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Truist Financial restated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Price Performance

NASDAQ:LNTH opened at $78.23 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $56.44 and a fifty-two week high of $126.89. The stock has a market capitalization of $5.44 billion, a PE ratio of 13.02 and a beta of 0.44. The business’s 50-day simple moving average is $90.31 and its 200-day simple moving average is $97.05.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.